<?xml version='1.0' encoding='utf-8'?>
<document id="28052338"><sentence text="Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model." /><sentence text="The objectives of the analysis were to develop and verify a venetoclax physiologically based pharmacokinetic (PBPK) model to predict the effects of cytochrome P450 3A (CYP3A) inhibitors and inducers on the PK of venetoclax and inform dosing recommendations" /><sentence text=" A minimal PBPK model was developed based on prior in vitro and in vivo clinical data using a &quot;middle-out&quot; approach" /><sentence text=" The PBPK model was independently verified against clinical studies of the strong CYP3A inhibitor ketoconazole, the strong CYP3A inducer, multiple-dose rifampin, and the steady-state venetoclax PK in chronic lymphocytic leukemia (CLL) subjects by comparing predicted to observed ratios of the venetoclax maximum concentration (Cmax R) and area under the curve from time 0 to infinity (AUC∞ R) from these studies"><entity charOffset="98-110" id="DDI-PubMed.28052338.s4.e0" text="ketoconazole" /><entity charOffset="152-160" id="DDI-PubMed.28052338.s4.e1" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.28052338.s4.e0" e2="DDI-PubMed.28052338.s4.e0" /><pair ddi="false" e1="DDI-PubMed.28052338.s4.e0" e2="DDI-PubMed.28052338.s4.e1" /></sentence><sentence text=" The verified PBPK model was then used to simulate the effects of different CYP3A inhibitors and inducers on the venetoclax PK" /><sentence text=" Comparison of the PBPK model predicted to the observed PK parameters indicated good agreement" /><sentence text=" Verification of the PBPK model demonstrated that the ratios of the predicted:observed Cmax R and AUC∞ R of venetoclax were within 0" /><sentence text="8- to 1" /><sentence text="25-fold range for strong CYP3A inhibitors and inducers" /><sentence text=" Model simulations indicated no effect of weak CYP3A inhibitors or inducers on Cmax or AUC∞ , while both moderate and strong CYP3A inducers were estimated to decrease venetoclax exposure" /><sentence text=" Moderate and strong CYP3A inhibitors were estimated to increase venetoclax AUC∞ , by 100% to 390% and 480% to 680%, respectively" /><sentence text=" The recommended venetoclax dose reductions of at least 50% and 75% when coadministered with moderate and strong CYP3A inhibitors, respectively, maintain venetoclax exposures between therapeutic and maximally administered safe doses" /><sentence text="" /></document>